Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca agrees takeover of Pearl Therapeutics

AstraZeneca agrees takeover of Pearl Therapeutics

10th June 2013

AstraZeneca has agreed a deal worth up to $1.15 billion (741.16 million pounds) to acquire the California-based healthcare company Pearl Therapeutics.

To be completed in the third quarter of 2013, the transaction will give AstraZeneca access to a potential new treatment for chronic obstructive pulmonary disease (COPD) that is currently in late-stage development, plus several inhaler and formulation technology offerings.

Pearl specialises in the development of inhaled small-molecule therapeutics for respiratory disease, with its lead product PT003 representing the first of a potentially important new class of treatment for COPD.

Pascal Soriot, chief executive officer of AstraZeneca, said: "The agreement will enable us to offer further distinctive treatment options across the full spectrum of COPD and asthma to patients, physicians and payers."

Last month, the firm agreed a $443 million deal to purchase Omthera Pharmaceuticals, a developer of new therapies for dyslipidaemia and the creator of the innovative drug Epanova, which has performed strongly in phase III clinical trials.ADNFCR-8000103-ID-801596654-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.